1. Home
  2. NCLH vs GKOS Comparison

NCLH vs GKOS Comparison

Compare NCLH & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Norwegian Cruise Line Holdings Ltd.

NCLH

Norwegian Cruise Line Holdings Ltd.

HOLD

Current Price

$19.78

Market Cap

8.4B

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$156.60

Market Cap

8.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCLH
GKOS
Founded
1966
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Marine Transportation
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.4B
8.7B
IPO Year
2011
2015

Fundamental Metrics

Financial Performance
Metric
NCLH
GKOS
Price
$19.78
$156.60
Analyst Decision
Buy
Strong Buy
Analyst Count
17
12
Target Price
$24.76
$126.92
AVG Volume (30 Days)
15.8M
768.7K
Earning Date
05-04-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.23
N/A
Revenue
$5,396,175,000.00
$507,442,000.00
Revenue This Year
$9.96
$23.32
Revenue Next Year
$6.60
$27.43
P/E Ratio
$84.63
N/A
Revenue Growth
10.71
32.33
52 Week Low
$14.53
$73.16
52 Week High
$27.18
$156.60

Technical Indicators

Market Signals
Indicator
NCLH
GKOS
Relative Strength Index (RSI) 51.90 70.99
Support Level $17.73 $96.44
Resistance Level $20.82 N/A
Average True Range (ATR) 0.83 6.26
MACD -0.17 0.87
Stochastic Oscillator 44.94 98.90

Price Performance

Historical Comparison
NCLH
GKOS

About NCLH Norwegian Cruise Line Holdings Ltd.

Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 17 passenger vessels on order among its brands through 2037, representing 46,000 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: